Notable Labs ran an automated laboratory in Foster City that exposed a patient's own leukaemia or lymphoma cells to combinations of approved drugs and measured which killed them, to predict which treatment would work. It listed on Nasdaq in 2023, but its website was offline in September 2026, so it is recorded as wound down.
Notable Labs built an automated laboratory in Foster City that exposed a patient's own leukaemia or lymphoma cells to combinations of approved drugs and measured which killed the cancer cells while sparing healthy ones, a functional precision medicine approach aimed at relapsed and refractory blood cancers. The company later listed on Nasdaq through a 2023 merger with Vascular Biogenics and pursued a predictive precision medicine platform around volasertib in acute myeloid leukaemia. The YC directory marks it Public, but its website did not resolve on 2026-09-10, so it is recorded as wound down pending a primary source; treat the status as uncertain.
Shares Y Combinator, Functional (ex vivo) drug testing and the tag yc.
Shares Y Combinator, Functional (ex vivo) drug testing and the tag yc.
Shares Y Combinator, Functional (ex vivo) drug testing and the tag yc.
Shares Y Combinator and the tag yc.
Shares Y Combinator and the tag yc.
Shares Y Combinator and the tag yc.
Shares Y Combinator and the tag yc.
Shares Y Combinator and the tag yc.